Postes actifs de Reinier Beeuwkes
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Braintree Laboratories, Inc.
 Braintree Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Braintree Laboratories, Inc. manufactures pharmaceutical products and drugs. Its products include SUPREP, NuLYTELY and GoLYTELY. The company was founded by Harry Keegan III and Reinier Beeuwkes in 1982 and is headquartered in Braintree, MA. | Directeur/Membre du Conseil | 01/01/1982 | - |
| Fondateur | 01/01/1982 | - | |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Directeur/Membre du Conseil | 01/01/2002 | - |
Historique de carrière de Reinier Beeuwkes
Anciens postes connus de Reinier Beeuwkes
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CITIUS PHARMACEUTICALS, INC. | Directeur Général | - | 12/09/2014 |
| Président | - | 12/09/2014 |
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Director/Board Member | 2 |
| Founder | 1 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CITIUS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Braintree Laboratories, Inc.
Braintree Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Braintree Laboratories, Inc. manufactures pharmaceutical products and drugs. Its products include SUPREP, NuLYTELY and GoLYTELY. The company was founded by Harry Keegan III and Reinier Beeuwkes in 1982 and is headquartered in Braintree, MA. | Health Technology |
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
- Bourse
- Insiders
- Reinier Beeuwkes
- Expérience
